Table 3.

Hazard ratio for outcomes among patients with elevated mean pulmonary artery pressure (mPAP) stratified by pulmonary vascular resistance (PVR), and further subgrouped by low and high pulmonary artery wedge pressure (PAWP).

Primary Cohort						Validation Cohort
		All-Cause Mortality: PVR ≥2.2 vs. <2.2 WU			Heart Failure Hospitalization: PVR ≥2.2 vs. <2.2 WU			All-Cause Mortality: PVR ≥2.2 vs. <2.2 WU
		Adjusted HR (95% CI)	Chi Square	P-Value	Adjusted HR (95% CI)	Chi Square	P-Value	Adjusted HR (95% CI)	Chi Square	P-Value
mPAP ≥19 mmHg	All PAWP	1.47 (1.42 – 1.53)	379.6	<0.0001	1.17 (1.11 – 1.24)	32.7	<0.0001	1.58 (1.31 – 1.91)	22.63	<0.0001
	PAWP >15 mmHg	1.36 (1.29 – 1.42)	163.7	<0.0001	1.15 (1.08 – 1.23)	19.7	<0.0001	1.44 (1.12 – 1.83)	8.43	0.0037
	PAWP ≤15 mmHg	1.71 (1.59 – 1.84)	214.0	<0.0001	1.27 (1.13 – 1.43)	16.2	0.0001	1.81 (1.33 – 2.47)	13.97	0.0002

Data for patients with mean pulmonary arterial pressure (mPAP) ≥19 mmHg stratified by PVR and then further subgrouped by low vs. high PAWP are presented for the primary cohort (VA-CART) and validation cohort (Vanderbilt University Medical Center) (VUMC) (1998–2014). Adjustment model included the following clinical variables: categorical age, sex, race, categorical body mass index, and history of systemic hypertension, congestive heart failure, left heart failure, diabetes mellitus, coronary artery disease, chronic obstructive pulmonary disease (COPD), liver cirrhosis, chronic kidney disease that included the patient receiving renal replacement therapy, portal hypertension, connective tissue disease, atrial arrhythmia, interstitial lung disease, pulmonary embolism, valvular disease, tobacco use, psychiatric disease, stroke, obstructive sleep apnea, and inpatient hospital status at the time of right heart catheterization. For the validation cohort, the following variables from the adjustment used in the primary cohort analysis were available and included: age, sex, race, diabetes mellitus, body mass index, coronary artery disease, valvular heart disease, COPD, atrial arrhythmia, interstitial lung disease, connective tissue disease, systemic hypertension, chronic kidney disease, obstructive sleep apnea, congestive heart failure. For both the primary and validation cohorts, the model for analyses of patients without restricting PAWP also included the co-variate of PAWP itself. Data are presented as hazard ratio (95% confidence interval) relative to the referent group of PVR<2.2 Wood units (WU).